

Substituted 1,2-Thiazetidine 1,1-Dioxides. Synthesis of (*RS*)- and (*S*)-1,2- Thiazetidine-3-acetic Acid 1,1-Dioxide and its Reactions with Amino Acids and Dipeptides

Till Röhrich, Bassam Abu Thaher, Nico Manicone,
and Hans-Hartwig Otto*

Department of Pharmaceutical/Medicinal Chemistry (PMC), Institute of Pharmacy,
Ernst-Moritz-Arndt-University, DE-17487 Greifswald, Germany

Received December 2, 2003; accepted December 5, 2003

Published online April 22, 2004 © Springer-Verlag 2004

Summary. (*RS*)-2-*tert*-Butyldimethylsilyl-1,2-thiazetidine-3-acetic acid 1,1-dioxide prepared from (*RS*)-*S*-benzyl- β -homocysteine was condensed *via* *DCC/NHS* with various *L*-amino acid esters or dipeptide esters yielding *N*-silylated β -sultam peptides. A β -sultam active ester was isolated as an intermediate. Desilylation with *TBAF* in *THF* yielded stable *N*-unsubstituted products, and deprotection of the benzyl esters was achieved by catalytic hydrogenation. (*S*)-*S*-Benzyl- β -homocysteine was obtained by fractional crystallization of the brucine salt of the racemate and transformed into benzyl (*S*)-1,2-thiazetidine-3-acetate, which was on the other hand synthesized by an enantiospecific route from ω -benzyl *Boc-L*-aspartate. Some β -sultam peptides were prepared from the (*S*)-enantiomer, and finally some β -sultam peptides containing *D-Ala* units were obtained.

Keywords. 1,2-Thiazetidine 1,1-Dioxide; β -Sultam; β -Sultam Peptide.

Introduction


In a preceding paper we have reported about the synthesis and properties of *N*-alkylated and *N*-acylated derivatives of (*RS*)-1,2-thiazetidine-3-acetic acid 1,1-dioxide [1], and compared their properties with those of analogue β -lactam peptides [2]. Here we report about preparation and properties of another type of the so-called β -sultam peptides, especially those oligopeptides in which the β -sultam ring forms the *N*-terminus. The *N*-silylated (*RS*)-1,2-thiazetidine-3-acetic acid 1,1-dioxide or the (*S*)-enantiomer were used as appropriate building blocks.

* Corresponding author. E-mail: ottohh@pharmazie.uni-greifswald.de


Results and Discussion

Synthesis

Benzyl (*RS*)-2-*tert*-butyldimethylsilyl-1,2-thiazetidene-3-acetate 1,1-dioxide (**2**) [3] was prepared from (*RS*)-*S*-benzyl- β -homocysteine (**1**) [4] by oxidative chlorination followed by ring closure with ammonia and silylation (Scheme 1). The acid **3** was prepared by hydrogenolysis in the presence of Pd-C. The (*S*)-enantiomer **8** was prepared by an analogue synthesis from (*S*)-*S*-benzyl- β -homocysteine (**5**). First, we tried to get **5** by enzymatic resolution of the benzyl ester of **1** [5] using lipase from *Candida cylindracea*, and porcine pancreatic lipase, but without success. It was finally obtained by fractional crystallization of the diastereomers of the brucine salt [6] of the *N*-formyl derivative **4** and deformylation. Compound **5** was then cyclized via the tosylate **6a** and the hydrochloride **6b** after oxidative chlorination to benzyl (*S*)- β -sultam-3-acetate (**7**). Silylation yielded **8**, which was debenzylated to the acid **9**. Compounds **7** and **8** were sensitive against hydrolysis, both were hydrolyzed to the taurine derivative **10** under mild conditions. In contrast, the acid **9** was obtained as a crystalline solid, which could be stored over a longer period. We could not isolate the pure (*R*)-enantiomer of **5** from the mother liquor of crystallization. In all experiments we isolated a mixture of diastereomers. The maximum ratio *R*:*S* was 6:4.



Scheme 1




Scheme 2

To prove that the stereochemical assignment of **5** was correct, we prepared **7** by an unambiguous alternative selective route from Boc-L-Asp(OBn) (**11**) [7]. Reduction with $\text{BH}_3\text{-THF}$ gave the alcohol **12** [8], which was transformed into the bromo derivative **13** using P(Ph)_3 and CBr_4 [9]. Reaction with NaH and benzylmercaptane gave the N-Boc benzylmercapto derivative **14**, from which after deprotection with trifluoroacetic acid the hydrochloride **6b** was obtained. Finally, oxidative chlorination and ring closure with ammonia yielded the pure (S)-enantiomer **7**, with yield of 93% (Scheme 2), and being identical with the compound **7** prepared via the first described route from **5** (Scheme 1).

The coupling of **3** with amino acid esters in CH_2Cl_2 via DCC [10] at room temperature yielded beside little of the β -sultam peptides the N-acylurea **16** as the main product, caused by a basic catalyzed $N \rightarrow O$ acyl migration, for which the amino acid ester or DCC could have act as a catalyst. Even at low temperatures (ice/salt cooling) it was not possible to suppress this side reaction entirely. A more effective route for the synthesis of the β -sultam peptides we found being the modified carbodiimide procedure [11], by which 2 equivalents of N-hydroxysuccinimide (NHS) were added to the reaction mixture, and by which the yield of N-silylated β -sultam peptides raised up to 90% (Scheme 3).


Compound **3** could also be condensed with NHS/DCC [12] to yield the active ester **17**, a stable and good crystallizable solid, which could be aminolysed by amino acid esters in CH_2Cl_2 yielding the β -sultam peptides **15**. However, there seems to be no advantage of this procedure compared with the modified carbodiimide procedure, as products had to be worked up in the same way by column chromatography (CC) and yields were finally significantly lower. Therefore, the N-silylated β -sultam peptides **15a–15k** finally were prepared by the modified method. They were isolated as viscous liquids, which could be stored in a refrigerator for several months.

Removal of protecting groups had to be done very carefully. All hydrolytic reactions of the ester groups with aqueous bases (NaOH, KOH) [13] were completely unsuitable, as hydrolysis of the β -sultam ring seemed to be the more



Scheme 3

favored reaction. Only the catalytic hydrogenation of **15h** and **15i** in *EtOH* with Pd-C/H₂ yielded the *N*-silylated β -sultam peptides **19h** and **19i** with nearly quantitative yields. Desilylation [14] of **15** was possible by treatment with *TBAF* and glacial acetic acid in *THF*. The crude products were purified by CC yielding the *N*-unprotected β -sultam peptide esters **18** with 70–80% yield. As **18a** and **18d** are relatively apolar, they were extracted by *AcOEt* from the silica gel, while the more polar compounds **18b** and **18g** had to be extracted with *MeOH*. Compounds **18b** and **18g** and the benzyl ester **18h** were obtained as colorless crystals, whereas the methyl ester **18a** was isolated as a viscous liquid. Desilylation of **15f** was even successful, but the product decomposed during CC. Therefore, we prepared **15k**, and by desilylation **18k**, a stable crystalline product. But not only the hydrogenation of **18k** with Pd-C/H₂ in *EtOH*, but also deprotection with ammonium formiate [15] in *EtOH* did not yield the desired product. The benzyl ether seems to be stable against these procedures, as **18k** was in all experiments either reisolated or completely destroyed, probably by autoprotolytic decomposition [16].




TBDMS = *tert*-Butyldimethylsilyl

Scheme 4

Starting with the enantiomer (*S*)-**9** we prepared the sultam dipeptide **22a** either by direct coupling with the dipeptide *L*-(NO₂)*Arg-Gly-OBn* or after isolation of **21**, which was then reacted with the dipeptide to **22a**. This was transformed by catalytic hydrogenation into the free acid **22b**, and by a desilylation reaction with *TBAF* into the *N*-deprotected **22c** (Scheme 4). Both are stable compounds. The isomeric compound **20a** was prepared from (*S*)-**9** with the dipeptide *Gly-L*-(NO₂)*Arg-OBn*, and by desilylation with *TBAF* **20b** became accessible.

By reactions of *Boc*-dipeptides with compound **3** (Scheme 5) in the presence of *DCC* and *NHS* we obtained the *N*-silylated sultam dipeptides **23a–23c** with yields up to 60%. The free acid **28** was prepared from **23a** by hydrogenation of the benzyl ester group, whereas desilylation with *TBAF* yielded the *N*-deprotected compounds **24a–24c** as colorless crystalline compounds with yields of 30–60%. The proline derivatives **25**, **26**, and **27** were obtained by an analogue reaction with the parent dipeptide *Boc-L-Ala-L-Pro-OBn*.

Finally, we studied the properties of some related compounds (Scheme 6). The sulfonyl urea **32** was obtained from the α,α -dimethylated β -sultam **29** [17] by reaction with phenyl isocyanate in the presence of dibutyltin dilaurate, and by reaction between **29** and benzyl bromoacetate **30** was prepared, which gave after hydrogenation and reaction with *Boc-D-Ala-D-Ala-OBn* in the presence of pentafluorophenol and *EDC* the *D-Ala-D-Ala* β -sultam **31**. The *D-Ala-D-Ala* (*S*)- β -sultam **33**, on the other hand, was obtained by reaction between the appropriate dipeptide and **8**, and the *D-Ala* (*R*)- β -sultam **35** was synthesized by oxidative cyclization of the dipeptide **34**.




Scheme 5

Stereochemistry and Spectroscopy

The optical purity of the β -sultam **7** was checked using $\text{Pr}(hfc)_3$, and comparing the spectra of (*RS*)-**7** with those of (*S*)-**7** prepared *via* the brucine salt route (ee = 86%), and with those of (*S*)-**7** prepared from the aspartic ester **11** (ee > 95%). Furthermore, both compounds gave nearly identical CD spectra with a maximum at $\lambda = 244$ nm and minima at $\lambda = 241$ and 246 nm.

The optical purity of the β -sultam peptides was checked by HPLC using a ChiraSpher NT column. The diastereomeric mixtures of **15**, **18**, and **19** gave 2 peaks, ratio around 1:1, whereas from the compounds **20** and **22** only one peak was found establishing that only one enantiomer was formed (as expected). Therefore, we conclude the optical purity being about 95%.

All β -sultam peptides showed infrared absorptions of the sulfonyl group in the region of $\bar{\nu} = 1315\text{--}1300$ and $1160\text{--}1140$ cm^{-1} . The absorptions near 3040 cm^{-1} are characteristic for 1,2-thiazetidine 1,1-dioxides, unsubstituted in position 4 [18]. In addition, there were found absorptions of the carbonyl groups from ester, acid, and amide at relevant positions. The IR spectra of free acids were characterized by



Scheme 6

carbonyl absorptions at $\bar{\nu} = 1740$ and 1630 cm^{-1} , and sulfonyl bands at $\bar{\nu} = 1300$ and 1160 cm^{-1} .

^1H NMR spectra of compounds **2–10** are characterized by the superposition of two ABX(M) systems. The first system originates from the protons 3-H, 4-H, and 4'-H, the second one belongs to the protons of the methylene group at C-3 (numbered as 5-H and 5'-H) and 3-H of the β -sultam ring. Characteristic coupling constants taken from the ^1H NMR spectra (300 MHz) of (*S*)-**7** with decoupling experiments were: $J_{5,5'} = 16.8$, $J_{4,4'} = 12.2$, $J_{3,4} = 5.5$, $J_{3,4'} = 7.0$, $J_{3,5} = 5.9$, and $J_{3,5'} = 7.6$ Hz.

Most ^1H and ^{13}C NMR spectra of the 1:1 mixtures of diastereomeric β -sultam peptides showed only one set of signals or small shift differences between 0 and 0.16 ppm of the two diastereomers. In some examples, the N-H (amide) showed for each diastereomer one separate proton signal, with differences in the shifts up to 0.2 ppm (**26**: $\delta = 6.32$ and 6.48 ppm, ratio 1:1). Furthermore, in some spectra we noticed differences in the shifts of 5-H and C-3/C-5 (**26**: $\delta = 2.55$ and 2.61 ppm, 5-H; $\delta = 37.70/37.89$ and $40.68/41.06$ ppm, C-3 and C-5). In general, the ^1H NMR spectra included ABX patterns of the protons 3-H, 4-H, and 4'-H similar to those of other 2,3 disubstituted 1,2-thiazetidines 1,1-dioxides [3], sometimes with an additional coupling $^4J_{4'/\text{N}} = 3$ Hz [19]. Further characterization was done by ^{13}C and

^1H - ^{13}C hetero NMR spectra. As the R_f values of the diastereomers exhibited only very small differences, a separation by chromatographic methods was not successful. From the coupling constants, $J_{\text{gem}} = 12\text{--}13$, $J_{\text{cis}} = 8\text{--}9$, and $J_{\text{trans}} = 3\text{--}4.5$ Hz, we deduce in agreement with calculations (Hyperchem 5.0) that most of the β -sultam peptides exist with a slightly folded β -sultam ring and a more or less linear orientated peptide chain.

Some of the β -sultam peptides were tested by standard procedures as inhibitors of HLE or PPE but no remarkable effects were noticed.

Experimental

Melting points: *Linström* apparatus (uncorrected); IR spectra (KBr): Perkin-Elmer IR 1310, Beckman IR 4240, IR 33; ^1H NMR spectra: Varian T 60 (60 MHz), Bruker WP 80 (80 MHz), WP 250 (250 MHz), AM 400 (400 MHz), Varian U-300 (300 MHz), room temperature, internal TMS, values from 80 MHz spectra in CDCl_3 , if not noted otherwise; MS spectra: Finnigan GC MS 4000, MAT 312, MAT 44 S; optical rotation: Polatron D; CD spectra: Jasco spectropolarimeter J-710; elemental analyses: Institute of Pharmacy, or Chemisches Laboratorium, University of Freiburg or Greifswald: the results agreed with the calculated values within experimental error. Tetrahydrofuran (THF) was stored over CaCl_2 or KOH, then refluxed with Na and benzophenone, and distilled prior to use. Other solvents were dried/purified according to literature procedures. HPLC with Chiralpack AD, ChiraSpher NT, *n*-heptane/*EtOH*, 1 ml/min, room temperature, UV 260 nm.

Abbreviations: *AcOEt* = Ethyl acetate; *BuLi* = *n*-Butyllithium, 15% in hexane; CC = Column chromatography (Silica gel 60, Merck 7734, 0.063–0.200 mm); *DCC* = Dicyclohexyl carbodiimide; *DE* = Diethyl ether; *EDC* = *N'*-(3-Dimethylaminopropyl)-*N*-ethyl carbodiimide; *HMPT* = Hexamethylphosphorotrisamide; *NHS* = *N*-Hydroxysuccinimide; *PE* = petroleum ether; *TBAF* = Tetrabutylammonium fluoride (1 M solution in THF), TLC = thin layer chromatography (DC Fertigplatten Silica gel 60 F₂₅₄, Merck 5549 or 5715).

For (*RS*)-3-amino-4-(benzylthio)butyric acid (**1**), (*RS*)-benzyl 2-(*tert*-butyldimethylsilyl)-1,2-thiazetidine-3-acetate 1,1-dioxide (**2**), (*RS*)-2-(*tert*-butyldimethylsilyl)-1,2-thiazetidine-3-acetic acid 1,1-dioxide (**3**), and (*RS*)-4-(benzylthio)-3-(formylamino)butyric acid (**4**) see Refs. [4], [3], [7] and [5].

(*S*)-4-(Benzylthio)-3-(formylamino)butyric acid brucine salt (**4a**) [5]

Compound **4** (12.6 g, 50 mmol), and brucine-dihydrate (23.0 g, 50 mmol) were dissolved in 100 cm³ of warm acetone (40%), the solution was stored at 1–3°C for 24 h, and the precipitate was separated. Yield 12 g (35%); colorless crystals; mp 67–70°C (H_2O), (Ref. [5] 65–70°C); $[\alpha]_{\text{D}}^{20} = -15.2^\circ \text{cm}^2 \text{g}^{-1}$ ($c = 1.92$, *EtOH*), (Ref. [5] $[\alpha]_{\text{D}}^{20} = -16.3^\circ \text{cm}^2 \text{g}^{-1}$ ($c = 1.97$, *EtOH*)).

(*S*)-3-Amino-4-(benzylthio)butyric acid (**5**) [5]

From the brucine salt **4a**. Yield 2.5 g (72%); prismatic crystals; mp 195–196°C (*EtOH*/ H_2O), (Ref. [5] 171–174°C); $[\alpha]_{\text{D}}^{20} = -59.2^\circ \text{cm}^2 \text{g}^{-1}$ ($c = 1.3$, 1 N HCl), (Ref. $[\alpha]_{\text{D}}^{20} = -64.0^\circ \text{cm}^2 \text{g}^{-1}$ ($c = 1.2$, 1 N HCl)).

The mother liquor of **4a** was evaporated, and the residue was purified as described. Yield 3.0 g (40%); mixture 60:40 of *R:S*; mp 195–197°C (H_2O); $[\alpha]_{\text{D}}^{20} = +24.5^\circ \text{cm}^2 \text{g}^{-1}$ ($c = 1.2$, 1 N HCl).

Benzyl (*S*)-3-amino-4-(benzylthio)butanoate tosylate (**6a**, $\text{C}_{25}\text{H}_{29}\text{NO}_5\text{S}_2$)

Compound **5** (5.1 g, 20 mmol), 4.5 g of *p*-toluenesulfonic acid monohydrate (24 mmol), and 12.19 g of benzylalcohol (113 mmol) in 150 cm³ of CHCl_3 were refluxed for 20 h in a water separator. The solution was concentrated to 1/3, 200 cm³ of *DE* were added, and after cooling to 3°C, the precipitate

was separated. Yield 6.3 g (88%); colorless crystals; mp 111–112°C (CHCl₃/PE); $[\alpha]_{\text{D}}^{20} = -4.5^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.12$, CHCl₃).

Benzyl (S)-3-amino-4-(benzylthio)butanoate hydrochloride (6b, C₁₈H₂₂ClNO₂S)

a) Compound **6a** (6.39 g, 12.9 mmol) was dissolved in a solution of Na₂CO₃ (120 cm³, 10%), the solution was extracted with 2 × 100 cm³ of DE, the organic layer was dried (Na₂SO₄), and with cooling the solution was saturated with dry HCl. The precipitate was separated. b) Compound **14** (2.5 g, 6.0 mmol), 9.5 cm³ of trifluoroacetic acid (120 mmol), and 3.5 cm³ of propane-2-thiol (60 mmol) were stirred for 2 h at 0°C. The mixture was evaporated *in vacuo*, a solution of NaCO₃ (100 cm³, 10%) was added, the mixture was extracted with 2 × 50 cm³ of DE, and the combined organic layers were dried (Na₂SO₄) and evaporated. The residue was dissolved in DE and saturated with HCl. After cooling to 0°C for 24 h, the precipitate was separated and dried *in vacuo*. Yield a) 3.9 g (86%); b) 2.1 g (99%); colorless crystals; mp 129–130°C (CHCl₃/DE); $[\alpha]_{\text{D}}^{20} = -11.7^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.06$, CHCl₃); IR: $\bar{\nu} = 3412\text{--}3150$ (NH₃⁺), 2915 (CH), 1714 (CO) cm⁻¹; ¹H NMR (300 MHz): $\delta = 2.79$ (dd, $J = 14.2$, 7.0 Hz, 2-H), 2.91 (dd, $J = 17.2$, 6.0 Hz, 4-H), 2.96 (dd, $J = 14.2$, 6.0 Hz, 2'-H), 3.03 (dd, $J = 17.2$, 6.4 Hz, 4'-H), 3.67 (quintet, $J = 6.6$ Hz, 3-H), 3.71 (s, SCH₂), 5.06, 5.11 (2d, each $J = 17.6$ Hz, OCH₂), 7.23 (m, 10arom H), 8.60 (s, NH₃⁺) ppm.

Benzyl (S)-1,2-thiazetidine-3-acetate 1,1-dioxide (7, C₁₁H₁₃NO₄S)

Compound **6b** (5.0 g, 14.3 mmol) was dissolved in a mixture of 80 cm³ of CHCl₃ and 60 cm³ of EtOH (96%), At 0°C, the mixture was saturated with Cl₂, then, the solution was concentrated to 1/3, 200 cm³ of DE were added, and the mixture was stored at -3°C for 24 h. The precipitate was separated and suspended in 200 cm³ of CHCl₃, and at 0°C neutralized by stepwise addition of a satd. solution of NH₃ in CHCl₃. 100 cm³ of AcOEt were added, the organic layer was washed with H₂O, then dried (Na₂SO₄), and evaporated *in vacuo*. Yield 2.8 g (78%); colorless plats; mp 82–83°C (isopropanol/DE); $[\alpha]_{\text{D}}^{20} = +12.91^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR: $\bar{\nu} = 3318$ (NH), 3053, 2995 (CH), 1723 (CO), 1340, 1163 (SO₂) cm⁻¹; ¹H NMR (300 MHz): $\delta = 2.82$ (dd, $J = 5.9$, 16.8 Hz, 5-H), 2.89 (dd, $J = 7.6$, 16.8 Hz, 5'-H), 3.89–4.01 (ddd, $J = 0.7$, 4.9, 12.2 Hz, 4-H), 4.02 (m, 3-H), 4.36 (ddd, $J = 3.3$, 7.3, 12.2 Hz, 4'-H), 5.15 (s, OCH₂), 5.65 (s, N-H), 7.35 (m, 5arom H) ppm; ¹³C NMR: $\delta = 37.25$ (C-5), 39.98 (C-3), 64.60 (C-4), 67.09 (OCH₂), 128.38, 128.63, 128.70, 135.07 (arom C), 169.86 (CO) ppm.

Benzyl (S)-2-(tert-butyldimethylsilyl)-1,2-thiazetidine-3-acetate 1,1-dioxide (8, C₁₇H₂₇NO₄SSi)

At -78°C 9.1 cm³ of BuLi (14.56 mmol) were added to a solution of **7** (3.7 g, 14.5 mmol) in 150 cm³ of THF. Then *tert*-butylchlorodimethylsilane (2.4 g, 16.0 mmol) in 20 cm³ of THF was added. The mixture was stirred for 15 min at -78°C, and slowly warmed until the solution became clear. After cooling to 0°C, the mixture was hydrolyzed with a satd. solution of NH₄Cl, the organic layer was separated, and the aqueous layer was extracted with 2 × 100 cm³ of AcOEt. The combined organic layers were dried (MgSO₄), and the solvent was evaporated *in vacuo*. Yield 2.4 g (49%); mp 78–79°C (cyclohexane:*n*-hexane = 1:1); $[\alpha]_{\text{D}}^{20} = -18.32^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.0$, EtOH); IR: $\bar{\nu} = 1735$ (CO), 1306, 1152 (SO₂) cm⁻¹; ¹H NMR (300 MHz): $\delta = 0.28$ [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 2.81 (ddt, $J = 2.0$, 10.0, 16.4 Hz, 5-H), 2.94 (dd, $J = 3.9$, 16.4 Hz, 5'-H), 3.95 (dd, $J = 13.4$, 3.7 Hz, 4-H), 3.96 (m, 3-H), 4.39 (ddd, $J = 13.4$, 9.0, 1.5 Hz, 4'-H), 5.12 (s, OCH₂), 7.37 (m, 5arom H) ppm.

(S)-2-(tert-Butyldimethylsilyl)-1,2-thiazetidine-3-acetic acid 1,1-dioxide (9, C₁₀H₂₁NO₄SSi)

From **8** (2.5 g, 7.1 mmol) in 250 cm³ of EtOH and 0.4 g of Pd-C (10%) by hydrogenolysis. Yield 1.4 g (70%); colorless crystals; mp 113–114°C (EtOH); $[\alpha]_{\text{D}}^{20} = -19.42^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.03$, EtOH);

IR: $\bar{\nu}$ = 3300–2800 (OH), 1700 (CO), 1305, 1152 (SO₂) cm⁻¹; ¹H NMR (300 MHz, MeOH-d₄): δ = 0.28 [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 2.72 (ddt, J = 16.4, 9.8, 3.4 Hz, 5-H), 2.91 (ddt, J = 16.4, 3.9, 1.8 Hz, 5'-H), 4.03 (dd, J = 13.7, 3.7 Hz, 3-H), 4.06 (dd, J = 3.7, 13.7 Hz, 4-H), 4.61 (dd, J = 7.7, 13.7 Hz, 4'-H) ppm.

(*S*)-2-Amino-4-oxo-4-benzoyloxybutane sulfonic acid (**10**, C₁₁H₁₅NO₅S)

From **7** (150 mg, 0.43 mmol) by hydrolysis with dil. HCl. Yield 100 mg (85%); colorless solid; mp 132–133°C (dec.); $[\alpha]_{\text{D}}^{20}$ = -8.6° cm² g⁻¹ (c = 0.35, DMSO); $[\alpha]_{\text{D}}^{27}$ = +18.0° cm² g⁻¹ (c = 0.5, 1 N HCl); IR: $\bar{\nu}$ = 3447 (NH₂), 1728 (CO), 1207, 1152, 1043 (SO₂) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆, 50°C): δ = 2.74 (dd, J = 14.2, 8.8 Hz, 3-H), 2.77 (dd, J = 17.1, 7.1 Hz, 1-H), 2.84 (dd, J = 14.2, 4.0 Hz, 3'-H), 2.92 (dd, J = 17.1, 6.4 Hz, 1'-H), 3.77 (m, 2-H), 5.12 (s, OCH₂), 7.32 (m, 5arom H), 7.88 (s, NH₂) ppm; MS(Fab-Gun Xe, 8 kV, 1 mA): m/z = 274 (M⁺ + 1), 273 (M⁺).

Boc-Asp(OBn)-OH (**11**)

Bachem A-1245.0100.

Benzyl (*S*)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (**12**) [7]

From Boc-Asp(OBn)OH (8 g, 24.8 mmol) in 30 cm³ of THF by reduction with BH₃-THF (1 N) under N₂ at 0°C. The residue (6.3 g) was purified by FC (AcOEt:cyclohexane = 1:1). Yield 3.6 g (47%); R_f = 0.43; colorless wax; mp 57°C (AcOEt/cyclohexane); $[\alpha]_{\text{D}}^{22}$ = -4.77° cm² g⁻¹ (c = 6, AcOEt).

Benzyl (*S*)-3-(tert-butoxycarbonylamino)-4-bromobutanoate (**13**) [8]

From **12** (3.6 g, 11.6 mmol) by reaction with P(Ph)₃ (3.05 g, 11.6 mmol) and CBr₄ (5.8 g, 17.4 mmol). The residue was purified by FC (AcOEt:cyclohexane = 1:4). Yield 2.7 g (63%); R_f = 0.45; colorless liquid; $[\alpha]_{\text{D}}^{24}$ = -0.80° cm² g⁻¹ (c = 6, AcOEt).

Benzyl (*S*)-3-(tert-butoxycarbonylamino)-4-(benzylthio)butanoate (**14**, C₂₃H₂₉NO₄S)

Under N₂ benzylmercaptan (1.1 cm³, 9.4 mmol) was added with cooling to a suspension of NaH (350 mg, 8.7 mmol, 60%) in 2 cm³ of DMF, then **13** (2.7 g, 7.25 mmol) dissolved in 6 cm³ of DMF was added, the mixture was stirred for 3 h, 100 cm³ of AcOEt were added, and the mixture was washed with a satd. solution of NH₄Cl (2 × 50 cm³). The organic layer was separated, dried (Na₂SO₄), and evaporated *in vacuo*. The residue was purified by FC (cyclohexane:AcOEt = 4:1). Yield 2.7 g (89%); colorless viscous solid; mp 42°C (AcOEt/cyclohexane); $[\alpha]_{\text{D}}^{26}$ = -7.58° cm² g⁻¹ (c = 6, AcOEt); R_f = 0.45; IR (film): $\bar{\nu}$ = 3450–3300 (NH), 2978 (CH), 1750, 1680 (CO), 1246 (C–N) cm⁻¹; ¹H NMR (300 MHz): δ = 1.45 [s, C(CH₃)₃], 2.55–2.76 (m, 2-H, 2'-H, 4-H, 4'-H), 3.72 (s, SCH₂), 4.10 (m, H-3), 5.07 (s, N–H), 5.10 (s, OCH₂), 7.21–7.38 (m, 10arom H) ppm.

General Procedure for the Reaction of **3** with Esters of L-Amino Acids or Dipeptides

Triethylamine (0.5 g, 5 mmol) was added to the amino acid ester/dipeptide ester salt (5 mmol) dissolved in 10 cm³ of CH₂Cl₂, the mixture was stirred for 5 min, filtered, and then **3** (0.7 g, 2.5 mmol), and NHS (0.58 g, 5 mmol) dissolved in 50 cm³ of CH₂Cl₂ were added. The mixture was cooled to -5°C, and DCC (0.65 g, 3.3 mmol) was added. After stirring for 20 h at -5°C, the precipitate was separated, and the organic layer was evaporated. The residue was dissolved in DE, and separated from insoluble precipitate. The solvent was evaporated, and the residue was purified by CC.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-phenylalanine methyl ester (**15a**, C₂₀H₃₂N₂O₅SSi)

From *L*-Phe-OMe-HCl (1.02 g, 5 mmol). Yield 950 mg (86%); colorless liquid; $[\alpha]_{\text{D}}^{20} = +34.9^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3320$ (NH), 1730, 1650 (CO), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.23$ [s, Si(CH₃)₂], 0.93 [s, C(CH₃)₃], 2.53 (m, 5-H, 5'-H), 3.70 (s, OCH₃), 3.05 [m, 2 β -H(*Phe*)], 3.95 (dd, $J = 4.0, 13.0$ Hz, 4-H), 4.04 (m, 3-H), 4.38 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.80 [m, α -H(*Phe*)], 6.49 (d, $J = 7.0$ Hz, N-H), 7.20 (m, 5arom H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}glycine methyl ester (**15b**, C₁₃H₂₆N₂O₅SSi)

From *Gly*-OMe-HCl (1.12 g, 10 mmol). Yield 1.65 g (94%); colorless platelets; mp 126°C (*DE*); IR: $\bar{\nu} = 3360$ (NH), 3040, 2920, 2940, 2850 (CH), 1740, 1670 (CO), 1520 (amide), 1290, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.25$ [s, Si(CH₃)₂], 0.95 [s, C(CH₃)₃], 2.78 (m, 5-H, 5'-H), 3.68 (s, OCH₃), 4.00 [m, 2 α -H(*Gly*)], 4-H, 3-H], 4.50 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 6.33 (s, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-methionine methyl ester (**15c**, C₁₆H₃₂N₂O₅S₂Si)

From *L*-Met-OMe-HCl (0.86 g, 5 mmol). Yield 930 mg (87%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +18.0^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.03$, CHCl₃); IR (film): $\bar{\nu} = 3325$ (NH), 3010, 2920, 2850 (CH), 1735, 1650 (CO), 1530 (amide), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.28$ [s, Si(CH₃)₂], 0.96 [s, C(CH₃)₃], 2.05 (s, SCH₃), 2.18 [m, 2 γ -H(*Met*)], 2.50 [m, 2 β -H(*Met*)], 2.83 (m, 5-H, 5'-H), 3.75 (s, OCH₃), 4.00 (dd, $J = 4.0, 13.0$ Hz, 4-H), 4.10 (m, 3-H), 4.52 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.65 [m, α -H(*Met*)], 6.80, 6.95 (d, $J = 7.0$ Hz, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-leucine methyl ester (**15d**, C₁₇H₃₄N₂O₅SSi)

From *L*-Leu-OMe-HCl (0.84 g, 5 mmol). Yield 850 mg (86%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +17.3^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3340$ (NH), 3030, 2920, 2950, 2850 (CH), 1740, 1650 (CO), 1530 (amide), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.30$ [s, Si(CH₃)₂], 0.95–1.00 [m, C(CH₃)₃, CH(CH₃)₂(*Leu*)], 1.63 [m, 2 β -H(*Leu*), γ -H(*Leu*)], 2.80 (m, 5-H, 5'-H), 3.73 (s, OCH₃), 4.02 (dd, 4-H), 4.10 (m, 3-H), 4.50 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.60 [m, α -H(*Leu*)], 6.60, 6.83 (d, $J = 7.0$ Hz, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-glutamic acid dimethyl ester (**15e**, C₁₇H₃₂N₂O₇SSi)

From *L*-Glu-(OMe)₂-HCl (1.84 g, 10 mmol). Yield 1.7 g (78%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +21.2^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3320$ (NH), 3030, 2920, 2950, 2850 (CH), 1740, 1665 (CO), 1530 (amide), 1305, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.30$ [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 2.15 [m, 2 γ -H(*Glu*)], 2.33 [m, 2 β -H(*Glu*)], 2.80 (m, 5-H, 5'-H), 3.58 [s, OCH₃(α)], 3.75 [s, OCH₃(δ)], 4.00 (dd, $J = 4.0, 13.0$ Hz, 4-H), 4.13 (m, 3-H), 4.52 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.60 [m, α -H(*Glu*)], 7.23, 7.33 (d, $J = 7.0$ Hz, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-serine methyl ester (**15f**, C₁₄H₂₈N₂O₆SSi)

From *L*-Ser-OMe-HCl (1.42 g, 10 mmol). Yield 1.1 g (58%); colorless solid; mp 87°C (*DE*); $[\alpha]_{\text{D}}^{20} = +15^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1$, CHCl₃); IR: $\bar{\nu} = 3341$ (NH), 3030, 2950, 2860 (CH), 1744, 1647 (CO), 1533 (amide), 1295, 1150, 1200 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.30$ [s, Si(CH₃)₂], 1.02 [s, C(CH₃)₃], 2.77 (dd, $J = 4.0, 10.5$ Hz, 5-H), 2.87 (dd, $J = 3.0, 10.5$ Hz, 5'-H), 3.02, 3.18 (t, $J = 5.0$ Hz, O-H), 3.80 (s, OCH₃),

3.88 [m, 2 β -H(*Ser*)], 4.06 (m, 4-H, 3-H), 4.52 (m, 4'-H), 4.64 [m, α -H(*Ser*)], 6.91, 7.05 (d, J = 8.0 Hz, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-cysteine ethyl ester (**15g**, C₁₅H₃₀N₂O₅S₂Si)

From *L*-Cys-OEt-HCl (1.58 g, 10 mmol). Yield 1.8 g (88%); viscous liquid; $[\alpha]_D^{20} = +20.5^\circ \text{ cm}^2 \text{ g}^{-1}$ (c = 3.6, CHCl₃); IR (film): $\bar{\nu}$ = 3340 (NH), 3030, 2930, 2860 (CH), 1735, 1670 (CO), 1530 (amide), 1305, 1150 (SO₂) cm⁻¹; ¹H NMR: δ = 0.30 [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 1.28 (t, J = 7.0 Hz, CH₃), 2.86 (m, 5-H, 5'-H), 2.98 [d, J = 7.0 Hz, 2 β -H(*Cys*)], 3.13, 3.20 (2s, S-H), 4.05 (m, CH₂), 4.20 (m, 4-H), 4.38 (m, 3-H), 4.50 (dd, J = 9.0, 15.0 Hz, 4'-H), 4.75 [m, α -H(*Cys*)], 6.88, 7.00 (d, J = 7.0 Hz, N-H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*L*-phenylalanine benzyl ester (**15h**, C₂₆H₃₆N₂O₅SSi)

From *L*-Phe-OBn-HCl (1.02 g, 5 mmol). Yield 950 mg (74%); viscous liquid; $[\alpha]_D^{20} = -7.8^\circ \text{ cm}^2 \text{ g}^{-1}$ (c = 1.8, CHCl₃); IR (film): $\bar{\nu}$ = 3340 (NH), 3080, 3030, 2930, 2950, 2850 (CH), 1735, 1660 (CO), 1530 (amide), 1305, 1150 (SO₂) cm⁻¹; ¹H NMR: δ = 0.28 [s, Si(CH₃)₂], 0.95 [s, C(CH₃)₃], 2.53 (m, 5-H, 5'-H), 3.08 [m, 2 β -H(*Phe*)], 3.85 (dd, J = 4.0, 13.0 Hz, 4-H), 3.95 (m, 3-H), 4.18 (dd, J = 9.0, 13.0 Hz, 4'-H), 4.90 [m, α -H(*Phe*)], 5.13 (s, OCH₂), 6.65, 6.75 (d, J = 7.0 Hz, N-H), 7.13, 7.25 (2s, 10arom H) ppm; MS (70 eV): m/z (%) = 518 (0.19, M⁺ + 1), 460 (2.73), 91 (100).

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}glycine benzyl ester (**15i**, C₁₉H₃₀N₂O₅SSi)

From *Gly*-OBn-*p*-Ts (1.1 g, 3.27 mmol). Yield 980 mg (90%); colorless solid; mp 72°C (*DE*); IR: $\bar{\nu}$ = 3380 (NH), 1740, 1670 (CO), 1525 (amide), 1300, 1145 (SO₂) cm⁻¹; ¹H NMR: δ = 0.27 [s, Si(CH₃)₂], 0.98 [s, C(CH₃)₃], 2.70 (dd, J = 9.75, 15.0 Hz, 5-H), 2.84 (dd, J = 4.5, 15.0 Hz, 5'-H), 3.93 (dd, J = 3.45, 13.5 Hz, 4-H), 3.90 [dd, J = 7.0, 20.0 Hz, α -H(*Gly*)], 4.04 (m, 3-H), 4.20 [dd, J = 7.0, 20.0 Hz, α' -H(*Gly*)], 4.44 (dd, J = 7.5, 13.0 Hz, 4'-H), 5.15 (s, CH₂), 6.60 (d, J = 7.0 Hz, N-H), 7.30 (s, 5arom H) ppm.

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}-*O*-benzyl-*L*-serine methyl ester (**15k**, C₂₁H₃₄N₂O₆SSi)

From *O*-Bn-*L*-Ser-OMe-HCl (1.72 g, 7 mmol). Yield 1.5 g (64%); colorless liquid; $[\alpha]_D^{20} = +12.9^\circ \text{ cm}^2 \text{ g}^{-1}$ (c = 2.3, AcOEt); IR (film): $\bar{\nu}$ = 3349 (NH), 3070, 3030, 2960, 2930, 2860 (CH), 1744, 1673 (CO), 1528 (amide), 1153, 1312 (SO₂) cm⁻¹; ¹H NMR: δ = 0.31 [s, Si(CH₃)₂], 1.05 [s, C(CH₃)₃], 2.77 (dd, J = 3.5, 12.5 Hz, 5-H), 3.46–4.15 [m, 2 β -H(*Ser*), 3-H, 4-H], 3.74 (s, OCH₃), 4.33–4.82 [m, α -H(*Ser*), 4'-H], 6.56, 6.64 (2d, J = 7.0 Hz, N-H), 7.33 (s, 5arom H) ppm; MS (70 eV): m/z (%) = 471 (7.65, M⁺), 57 (100, C(CH₃)₃⁺), 413 (22.95), 115 (13.91), 91 (94.43).

N-{2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl}dicyclohexylurea (**16**, C₂₃H₄₃N₃O₄SSi)

As a by-product in reactions of **3** with esters of *L*-amino acids or dipeptides. Yield 10–30%; colorless crystals; mp 169°C (*DE*); IR: $\bar{\nu}$ = 3330 (NH), 1700, 1650 (CO), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: δ = 0.28 [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 1.27–1.77 (m, 22 cyclohexyl H), 2.78 (dd, J = 11.0, 15.0 Hz, 5-H), 3.03 (dd, J = 5.0, 15.0 Hz, 5'-H), 3.95 (dd, J = 4.0, 13.0 Hz, 4-H), 4.03 (m, 3-H), 4.53 (dd, J = 13.0, 9.0 Hz, 4'-H), 6.50 (d, J = 7.0 Hz, N-H) ppm.

2,5-Dioxopyrrolidinyl (RS)-2-(tert-butyl dimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-acetate
(**17**, C₁₄H₂₄N₂O₆SSi)

See **21**.

General Procedure for the Desilylation of 15

Glacial acetic acid (0.075 g, 1.25 mmol) and 1.25 cm³ of TBAF (1.25 mmol) were added to **15** (1.25 mmol) dissolved in 10–30 cm³ of THF at 0°C. The mixture was stirred for 10 min, diluted with 20–30 cm³ of THF, and then extracted with 30 cm³ of a 1:1 mixture of a satd. NaCl- and a satd. NaHCO₃-solution. The organic layer was separated, dried (Na₂SO₄), evaporated, and the residue was purified by CC (silica gel) with AcOEt, if not noted otherwise.

N-[(RS)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-L-phenylalanine methyl ester
(**18a**, C₁₄H₁₈N₂O₅S)

From **15a** (950 mg, 2.15 mmol). Yield 521 mg (78%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +4.25^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.2$, CHCl₃); IR (film): $\bar{\nu} = 3350$ (NH), 3060, 3030, 2970, 2880 (CH), 1745, 1660 (CO), 1540 (amide), 1310, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 2.58$ (m, 5-H, 5'-H), 3.03 [m, 2 β -H(*Phe*)], 3.63 (s, OCH₃), 3.93 (dd, $J = 4.0, 13.0$ Hz, 4-H), 4.16 (m, 3-H), 4.28 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.73 [m, α -H(*Phe*)], 6.33 (d, $J = 13.0$ Hz, N-H), 7.03, 6.90 (2d, $J = 9.0$ Hz, N-H), 7.15 (m, 5arom H) ppm.

N-[(RS)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]glycine methyl ester (**18b**, C₇H₁₂N₂O₅S)

From **15b** (1.0 g, 2.85 mmol), CC (AcOEt:MeOH = 1:1). Yield 150 mg (22%); colorless solid; mp 113°C (CHCl₃); IR: $\bar{\nu} = 3305$ (NH), 3080, 3040, 2960 (CH), 1753, 1643 (CO), 1547 (amide), 1323, 1165 (SO₂) cm⁻¹; ¹H NMR (100 MHz): $\delta = 2.72, 2.78$ (2dd, $J = 5.0, 10.5$ Hz, 5-H, 5'-H), 3.74 (s, OCH₃), 4.00 [m, 2 α -H(*Gly*)], 4-H, 3-H], 4.39 (dd, $J = 8.0, 14.0$ Hz, 4'-H), 6.88 (s, N-H), 7.63 (s, N-H) ppm.

N-[(RS)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-L-methionine methyl ester
(**18c**, C₁₀H₁₈N₂O₅S₂)

From **15c** (0.49 g, 1.25 mmol). Yield 220 mg (57%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +11.3^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3400$ (NH), 2950, 2920, 2860 (CH), 1730, 1650 (CO), 1540 (amide), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 2.05$ (s, SCH₃), 2.18 [m, 2 γ -H(*Met*)], 2.50 [m, 2 β -H(*Met*)], 2.80 (d, $J = 7.0$ Hz, 5-H, 5'-H), 3.75 (s, OCH₃), 4.05 (m, 4-H), 4.27 (m, 3-H), 4.38 (m, 4'-H), 4.63 [m, α -H(*Met*)], 6.83 (s, N-H), 7.80 (d, $J = 9.0$ Hz, N-H) ppm; MS (70 eV): m/z (%) = 311 (4.99, M⁺ + 1), 140 (11.92).

N-[(RS)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-L-leucine methyl ester
(**18d**, C₁₁H₂₀N₂O₅S)

From **15d** (0.53 g, 1.25 mmol), CC (acetone). Yield 250 mg (68%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +7.52^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.0$, CHCl₃); IR (film): $\bar{\nu} = 3300$ (NH), 3060, 3030, 2920, 2850 (CH), 1730, 1650 (CO), 1535 (amide), 1300, 1150 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.90$ (d, 2CH₃), 1.66 [m, 2 β -H(*Leu*), γ -H(*Leu*)], 2.70 (d, $J = 7.0$ Hz, 5-H, 5'-H), 3.63 (s, OCH₃), 4.03 (dd, $J = 4.0, 13.0$ Hz, 4-H), 4.03 (m, 3-H), 4.40 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.62 [m, α -H(*Leu*)], 6.88 (s, N-H), 7.00 (d, $J = 9.0$ Hz, N-H) ppm; MS (70 eV): m/z (%) = 293 (1.42, M⁺ + 1), 140 (4.91).

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-glutamic acid dimethyl ester
(**18e**, C₁₁H₁₈N₂O₇S)

From **15e** (1.5 g, 3.4 mmol). Yield 200 mg (18%); viscous liquid; $[\alpha]_{\text{D}}^{20} = +10.2^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.0$, CHCl₃); IR (film): $\bar{\nu} = 3321$ (NH), 3040, 2960, 2850 (CH), 1740, 1658 (CO), 1544 (amide), 1320, 1156 (SO₂) cm⁻¹; ¹H NMR (100 MHz): $\delta = 2.07, 2.20$ [2m, 2 β -H(*Glu*)], 2.42 [m, 2 γ -H(*Glu*)], 2.70, 2.78 (2d, $J = 4.5, 10.5$ Hz, 5-H, 5'-H), 3.69, 3.68 [2s, OCH₃(α)], 3.75, 3.77 [2s, OCH₃(δ)], 4.06 (m, 3-H, 4-H), 4.57 (dd, $J = 8.0, 14.0$ Hz, 4'-H), 4.41 [m, α -H(*Glu*)], 6.37, 6.35 (2s, N-H), 7.00, 6.93 (2d, $J = 8.0$ Hz, N-H) ppm; MS (70 eV): m/z (%) = 323 (100, M⁺+1), 291 (9.82), 259 (15.34).

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-cysteine ethyl ester (**18g**, C₉H₁₆N₂O₅S₂)

From **15g** (1.5 g, 3.65 mmol). Yield 700 mg (65%); colorless crystals; mp 112–114°C (CHCl₃/*DE*); $[\alpha]_{\text{D}}^{20} = +30.0^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.6$, CHCl₃); IR: $\bar{\nu} = 3323$ (NH), 2555 (SH), 1746, 1649 (CO), 1534 (amide), 1310, 1155 (SO₂) cm⁻¹; ¹H NMR (100 MHz): $\delta = 1.31$ (t, $J = 5.5$ Hz, CH₃), 1.40 (t, $J = 5.5$ Hz, S-H), 2.79 (ddd, $J = 3.4, 5.7, 10.5$ Hz, 5-H, 5'-H), 3.01 [m, 2 β -H(*Cys*)], 4.04 (m, CH₂), 4.25 (m, 3-H, 4-H), 4.42 (dd, $J = 8.0, 14.0$ Hz, 4'-H), 4.82 [m, α -H(*Cys*)], 6.13, 7.18 (s, N-H), 6.72, 6.76 (d, $J = 7.0$ Hz, N-H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-phenylalanine benzyl ester
(**18h**, C₂₀H₂₂N₂O₅S)

From **15h** (1.9 g, 3.68 mmol). Yield 900 mg (61%); colorless solid; mp 91°C (*DE*/acetone); $[\alpha]_{\text{D}}^{20} = +10.71^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.2$, CHCl₃); IR: $\bar{\nu} = 3320$ (NH), 3060, 3030, 2850 (CH), 1720, 1640 (CO), 1530 (amide), 1310, 1155 (SO₂) cm⁻¹; ¹H NMR (acetone-*d*₆): $\delta = 2.53$ (d, $J = 7.0$ Hz, 5-H, 5'-H), 3.08 [m, 2 β -H(*Phe*)], 3.80 (m, 4-H), 3.93 (m, 3-H), 4.18 (m, 4'-H), 4.75 [m, α -H(*Phe*)], 5.08 (s, OCH₂), 6.83 (s, N-H), 7.18, 7.33 (2s, 10arom H), 7.63 (d, $J = 7.0$ Hz, N-H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]glycine benzyl ester (**18i**, C₁₃H₁₆N₂O₅S)

From **15i** (0.53 g, 1.25 mmol). Yield 0.23 g (76%); colorless solid; mp 132°C (*DE*); IR: $\bar{\nu} = 3320$ (NH), 3070, 3030, 2970, 2950, 2850 (CH), 1750, 1640 (CO), 1540 (amide), 1310, 1155 (SO₂) cm⁻¹; ¹H NMR (*DMSO*-*d*₆): $\delta = 2.63$ (d, $J = 7.0$ Hz, 5-H, 5'-H), 3.90 [d, $J = 7.0, 2\alpha$ -H(*Gly*)], 4.02 (m, 3-H, 4-H), 4.33 (m, 4'-H), 5.08 (s, CH₂), 7.38 (s, 5arom H), 7.90 (s, N-H), 8.45, 8.55 (d, $J = 7.0$ Hz, N-H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*O*-benzyl-*L*-serine methyl ester
(**18k**, C₁₅H₂₀N₂O₆S)

From **15k** (1.0 g, 2.1 mmol). Yield 450 mg (60%); colorless solid; mp 144°C (*AcOEt*); $[\alpha]_{\text{D}}^{20} = +19.7^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.3$, *AcOEt*); IR: $\bar{\nu} = 3412$ (NH), 3070, 3040, 3000, 2960, 2930, 2900, 2850 (CH), 1753, 1666, 1627 (CO), 1518 (amide), 1319, 1151 (SO₂) cm⁻¹; ¹H NMR: $\delta = 2.70, 2.73$ (d, $J = 6.0$ Hz, 5-H, 5'-H), 3.73 (s, OCH₃), 3.73 (m, 4-H), 3.87 (m, 3-H), 4.00 [m, 2 β -H(*Ser*)], 4.25 (m, 4'-H), 4.25 [s, CH₂(*Bn*)], 4.70 [m, α -H(*Ser*)], 5.82, 6.06 (2s, N-H), 6.51 (m, N-H), 7.28 (s, 5arom H) ppm; MS (70 eV): m/z (%) = 356 (25.39, M⁺), 91 (100), 65 (15.95).

General Procedure for the Hydrogenolysis of Benzyl Esters 15

The benzyl ester **15** (10 mmol) dissolved in 100 cm³ of *EtOH*, and Pd-C (0.2 g, 10%) were hydrogenated at 100 kPa for 10–20 min. The catalyst was removed, and the solvent was evaporated *in vacuo*.

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]-*L*-phenylalanine (**19h**, C₁₉H₃₀N₂O₅SSi)

From **15h** (0.39 g, 7.5 mmol). Yield 0.32 g (98%); colorless solid; mp 45°C; $[\alpha]_{\text{D}}^{20} = -29^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.5$, CHCl₃); IR: $\bar{\nu} = 3400$ (NH, OH), 3030, 2920, 2950 (CH), 1735, 1650 (CO), 1550 (amide), 1305, 1150 (SO₂) cm⁻¹; ¹H NMR (acetone-d₆): $\delta = 0.25$ [s, Si(CH₃)₂], 0.95 [s, C(CH₃)₃], 2.75 (m, 5-H, 5'-H), 3.13 [m, 2 β -H(*Phe*)], 3.95 (dd, $J = 4.0, 13.0$ Hz, 4-H), 3.98 (m, 3-H), 4.33 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 4.75 [m, α -H(*Phe*)], 5.20 (s, COOH), 7.2 (s, 5arom H), 7.65 (d, $J = 9.0$ Hz, N-H) ppm.

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]glycine (**19i**, C₁₂H₂₄N₂O₅SSi)

From **15i** (0.32 g, 7.5 mmol). Yield 0.25 g (94%); colorless solid; mp 125°C (*DE*); IR: $\bar{\nu} = 3380$ (NH), 3050, 2930, 2950, 2870 (CH), 1770, 1660 (CO), 1570 (amide), 1300, 1155 (SO₂) cm⁻¹; ¹H NMR (acetone-d₆): $\delta = 0.30$ [s, Si(CH₃)₂], 0.98 [s, C(CH₃)₃], 2.70 (dd, $J = 11.0, 15.0$ Hz, 5-H), 3.03 (dd, $J = 5.0, 15.0$ Hz, 5'-H), 3.95 [d, $J = 7.0$ Hz, 2 α -H(*Gly*)], 3.95 (m, 4-H), 4.04 (m, 3-H), 4.50 (dd, $J = 13.0, 9.0$ Hz, 4'-H), 7.65 (s, N-H) ppm.

N-[2-[(*S*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]glycyl-*L*-nitroarginine benzyl ester (**20a**, C₂₅H₄₁N₇O₈SSi)

Compound **21** (0.7 g, 2.0 mmol) dissolved in 100 cm³ of *THF* was added to a mixture of 1.1 cm³ of triethylamine (7.4 mmol) and *Boc-Gly-L-Arg*(NO₂)-*OBn*-HCl (3.0 g, 7.4 mmol) in 150 cm³ of *MeCN* at -10°C. After stirring for 3 days at room temperature, the mixture was filtered, the solvent evaporated, and the residue was purified by CC (*AcOEt:EtOH* = 5:1, $R_{\text{f}} = 0.44$). Yield 350 mg (28%); colorless solid; mp 85–87°C; $[\alpha]_{\text{D}}^{20} = -18.6^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 0.3$, *EtOH*); IR: $\bar{\nu} = 3320$ (NH), 2931, 2860 (CH), 1740, 1629 (CO), 1534 (NO₂), 1300, 1256, 1150 (SO₂) cm⁻¹; ¹H NMR (300 MHz, *MeOH*-d₄): $\delta = 0.22$ [s, Si(CH₃)₂], 1.01 [s, C(CH₃)₃], 1.6–1.95 [m, 2 β -CH₂(*Arg*), 2 δ -CH₂(*Arg*)], 2.60 (ddd, $J = 2.2, 10.3, 14.7$ Hz, 5-H), 2.90 (ddd, $J = 2.0, 3.6, 14.7$ Hz, 5'-H), 3.23 [m, 2 γ -CH₂(*Arg*)], 3.84, 3.95 [dd, $J = 6.1, 16.6$ Hz, CH₂(*Gly*)], 4.06 (m, 3-H), 4.08 (dd, $J = 3.7, 13.7$ Hz, 4-H), 4.50 (dd, $J = 8.6, 13.7$ Hz, 4'-H), 4.52 [m, α -H(*Arg*)], 5.14, 5.20 (2d, $J = 12.2$ Hz, OCH₂), 7.38 (m, 5arom H) ppm; MS (FAB 26 kv 13): $m/z = 628$ (M⁺+1), 570 (M⁺-C(CH₃)₃), 154, 136, 107.

N-[(*S*)-(1,1-Dioxo-1,2-thiazetidene-3-yl)acetyl]-glycyl-*L*-nitroarginine benzyl ester (**20b**, C₁₉H₂₇N₇O₈S)

From **20a** (200 mg, 0.3 mmol) by desilylation, purification by CC (*AcOEt:EtOH* = 5:1). Yield 100 mg (61%); colorless solid; mp 100°C (dec); $[\alpha]_{\text{D}}^{20} = -17.7^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 0.4$, *EtOH*); IR: $\bar{\nu} = 3308$ (NH), 2940 (CH), 1740, 1654 (CO), 1534 (NO₂), 1290, 1264, 1041 (SO₂) cm⁻¹; ¹H NMR (300 MHz, 2D-Cosy, *MeOH*-d₄): $\delta = 1.62$ [m, 2 γ -CH₂(*Arg*)], 1.76–1.92 [m, 2 β -CH₂(*Arg*)], 2.69 (dd, $J = 6.3, 17.0$ Hz, 5-H), 2.75 (dd, $J = 6.8, 17.0$ Hz, 5'-H), 3.23 [m, 2 δ -CH₂(*Arg*)], 3.86 [dd, $J = 6.0, 16.6$ Hz, α -CH(*Gly*)], 3.91 [dd, $J = 4.1, 16.6$ Hz, α -CH(*Gly*)], 3.95 (m, 3-H), 4.04 (dd, $J = 5.3, 12.9$ Hz, 4-H), 4.39 (dd, $J = 7.8, 12.9$ Hz, 4'-H), 4.53 [m, α -CH(*Arg*)], 5.14, 5.20 (2d, $J = 12.2$ Hz, OCH₂), 7.38 (m, 5arom H) ppm; MS (FAB 26 kv 3): $m/z = 532$ (M⁺+Na), 514 (M⁺+1), 469 (M⁺-NO₂), 107, 136, 154.

2,5-Dioxopyrrolidinyl (*S*)-2-(*tert*-butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-acetate (**21**, C₁₄H₂₄N₂O₆SSi)

DCC (0.60 g, 3.0 mmol) in 20 cm³ of *THF* was added to a solution of (*S*)-**9** (0.70 g, 2.5 mmol) and *NHS* (0.71 g, 6.3 mmol) in 50 cm³ of *THF* at -12°C. After stirring for 1 h, the mixture was filtered, the

solvent evaporated, the residue dissolved in *AcOEt*, again filtered, and the solvent evaporated. Yield 0.90 g (96%); colorless solid; mp 151°C (*CHCl*₃/*PE*); $[\alpha]_{\text{D}}^{20} = -1.8^{\circ} \text{cm}^2 \text{g}^{-1}$ ($c = 1.1$, *CH*₂*Cl*₂); $R_{\text{f}} = 0.45$ (*CHCl*₃:*MeOH* = 1:1); IR: $\bar{\nu} = 3050, 2950, 2920, 2850$ (CH), 1810, 1785, 1730 (CO) 1306, 1152 (*SO*₂) cm^{-1} ; ¹H NMR (300 MHz): $\delta = 0.28$ [s, Si(*CH*₃)₂], 1.00 [s, C(*CH*₃)₃], 2.82 (s, 2*CH*₂), 3.16 (dd, $J = 4.0, 16.1$ Hz, 5-H), 3.10 (dd, $J = 9.8, 16.1$ Hz, 5'-H), 4.01 (m, 3-H), 4.06 (dd, $J = 3.7, 13.7$ Hz, 4-H), 4.61 (dd, $J = 8.1, 13.7$ Hz, 4'-H) ppm.

N-[2-[(*S*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]-*L*-nitroarginylglycine benzyl ester (**22a**, C₂₅H₄₁N₇O₈SSi)

From *L*-Arg(*NO*₂)-*Gly*-*OBn*-HCl (2.17 g, 5.3 mmol) and **21** (1.02 g, 2.7 mmol) as described for **20**. CC (*CHCl*₃:*MeCN*:*AcOEt* = 3:8:5, *EtOH*:*AcOEt*:cyclohexane = 1:2:4, *CHCl*₃:*MeOH* = 12:1). Yield 250 mg (14.7%); colorless crystals; mp 94–95°C; $R_{\text{f}} = 0.35$ (*CHCl*₃:*MeOH* = 12:1); $[\alpha]_{\text{D}}^{20} = -33.7^{\circ} \text{cm}^2 \text{g}^{-1}$ ($c = 0.7$, *EtOH*); IR: $\bar{\nu} = 3419$ (NH), 2955, 2930 (CH), 1738, 1960, 1650 (CO), 1290, 1256, 1150 (*SO*₂) cm^{-1} ; ¹H NMR (300 MHz, 2D-Cosy, acetone-*d*₆): $\delta = 0.25$ [s, Si(*CH*₃)₂], 0.97 [s, C(*CH*₃)₃], 1.70 [m, β -*CH*₂(*Arg*), δ -*CH*₂(*Arg*)], 2.73 (m, 5-H), 2.99 (ddd, $J = 3.9, 8.7, 15.1$ Hz, 5'-H), 3.37 [m, γ -*CH*₂(*Arg*)], 4.01 [m, 4-H, 3-H, *CH*₂(*Gly*)], 4.51 [m, 4'-H, α -*CH*(*Arg*)], 5.18 (s, *OCH*₂), 7.38 (m, 5arom H), 7.74–7.58 (m, 5N-H) ppm; MS (FAB 26 kv 3): $m/z = 628$ ($\text{M}^+ + 1$), 570 ($\text{M}^+ - \text{C}(\text{CH}_3)_3$), 154, 136, 107.

N-[2-[(*S*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]-*L*-nitroarginylglycine (**22b**, C₁₈H₃₅N₇O₈SSi)

From **22a** (100 mg, 0.16 mmol) by hydrogenolysis. Yield 50 mg (59%); colorless solid; mp 145°C; $[\alpha]_{\text{D}}^{20} = -16.0^{\circ} \text{cm}^2 \text{g}^{-1}$ ($c = 0.12$, isopropanol); IR: $\bar{\nu} = 3428$ (OH, NH), 2935, 2925 (CH), 1720, 1660, 1648 (CO), 1535 (*NO*₂), 1288, 1152 (*SO*₂) cm^{-1} ; ¹H-NMR (300 MHz, 2D-Cosy, *MeOH*-*d*₄): $\delta = 0.29$ [s, Si(*CH*₃)₂], 1.01 [s, C(*CH*₃)₃], 1.69 [m, 2 β -*CH*₂(*Arg*)], 1.88 [m, 2 γ -*CH*₂(*Arg*)], 2.6 (ddd, $J = 15.0, 9.9, 2.4$ Hz, 5-H), 2.96 (ddd, $J = 15.0, 9.4, 3.8$ Hz, 5'-H), 3.24 [m, 2 δ -*CH*₂(*Arg*)], 3.87 [m, $J = 17.4, 9.1$ Hz, *CH*₂(*Gly*)], 4.04 (m, 3-H), 4.11 (dd, $J = 13.4, 3.7$ Hz, 4-H), 4.37 [m, α -*CH*(*Arg*)], 4.54 (ddd, $J = 13.4, 7.7, 1.5$ Hz, 4'-H) ppm.

N-[(*S*)-(1,1-Dioxo-1,2-thiazetidene-3-yl)acetyl]-*L*-nitroarginylglycine benzyl ester (**22c**, C₁₉H₂₇N₇O₈S)

From **22a** (200 mg, 0.3 mmol) by desilylation. CC (*CHCl*₃:*MeOH* = 12:1). Yield 100 mg (61%); mp 89–90°C; $[\alpha]_{\text{D}}^{20} = -18.0^{\circ} \text{cm}^2 \text{g}^{-1}$ ($c = 0.1$, isopropanol); IR: $\bar{\nu} = 3380$ (NH), 3035, 2949 (CH), 1734, 1647 (CO), 1534, 1400 (*NO*₂), 1300, 1291, 1157 (*SO*₂) cm^{-1} ; ¹H NMR (300 MHz, acetone-*d*₆): $\delta = 1.7$ [m, 2 β -*CH*₂(*Arg*), 2 γ -*CH*₂(*Arg*)], 3.00 (m, 5-H, 5'-H), 3.34 [m, 2 δ -*CH*₂(*Arg*)], 4.01 [m, 3-H, 4-H, *CH*₂(*Gly*)], 4.35 (ddd, $J = 1.7, 7.6, 13.2$ Hz, 4'-H), 4.54 [m, α -*CH*(*Arg*)], 5.18 (s, *OCH*₂), 7.00 (s, N-H), 7.36 (m, 5arom H), 7.32–8.0 (m, 5N-H) ppm.

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidene-3-yl]acetyl]-*L*-alanylglycine benzyl ester (**23a**, C₂₂H₃₅N₃O₆SSi)

From **3** and *L*-Ala-*Gly*-*OBn*-HCl (1.86 g, 6 mmol) as described for **15**. Yield 0.52 g (42%); colorless liquid; $[\alpha]_{\text{D}}^{20} = +0.95^{\circ} \text{cm}^2 \text{g}^{-1}$ ($c = 1.1$, *CHCl*₃); IR (film): $\bar{\nu} = 3300$ (NH), 1740, 1650 (CO), 1530 (NH), 1300, 1150 (*SO*₂) cm^{-1} ; ¹H NMR: $\delta = 0.28$ [s, Si(*CH*₃)₂], 1.00 [s, C(*CH*₃)₃], 1.37 (d, $J = 9.0$ Hz, *CH*₃), 2.75 (m, 5-H, 5'-H), 3.98 (dd, $J = 4.0, 13.0$ Hz, 4-H), 3.98 (m, 3-H), 4.11 [d, $J = 7.0$ Hz, 2 α -H(*Gly*)], 4.53 (dd, $J = 9.0, 13.0$ Hz, 4'-H) 4.53 [m, α -H(*Ala*)], 5.18 (s, *CH*₂), 7.03 (m, 2N-H), 7.35 (s, 5arom H) ppm; MS: m/z (%) = 498 (3.56, $\text{M}^+ + 1$), 57 (17.12, C(*CH*₃)₃⁺), 91 (100, benzyl).

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl]-*L*-phenylalanylglycine methyl ester (**23b**, C₂₂H₃₅N₃O₆SSi)

From **3** and *L*-Phe-Gly-OMe-HCl (1.6 g, 6.8 mmol) as **23a**. Yield 1.3 g (52%); colorless crystals; mp 110°C (*DE*); $[\alpha]_{\text{D}}^{20} = -18.53^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR: $\bar{\nu} = 3301$ (NH), 1754, 1643 (CO), 1545 (NH), 1365, 1313, 1152 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.27$ [s, Si(CH₃)₂], 1.00 [s, C(CH₃)₃], 1.67 (m, 5-H, 5'-H), 3.05 [m, 2 β -H(*Phe*)], 3.52 (dd, $J = 3.0, 13.0$ Hz, 4-H), 3.75 (s, OCH₃), 4.00 (m, 3-H), 4.00 [d, $J = 6.0$ Hz, 2 α -H(*Gly*)], 4.30 [m, α -H(*Phe*)], 4.86 (dd, $J = 9.0, 13.0$ Hz, 4'-H), 6.75, 6.87, 7.00 (3d, each $J = 7.0$ Hz, N-H), 7.22 (s, 5arom H) ppm.

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl]-*L*-alanyl-*L*-phenylalanine methyl ester (**23c**, C₂₃H₃₇N₃O₆SSi)

From **3** and *L*-Ala-*L*-Phe-OMe-HCl (2.87 g, 10 mmol) as **23a**. Yield 2.4 g (63%); colorless liquid; $[\alpha]_{\text{D}}^{20} = +21.5^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3332$ (NH), 1739, 1648 (CO), 1535 (amide), 1366, 1152 (SO₂) cm⁻¹; ¹H NMR: $\delta = 0.29$ [s, Si(CH₃)₂], 1.01 [s, C(CH₃)₃], 1.34 (d, $J = 7.0$ Hz, CH₃), 2.70 (m, 5-H, 5'-H), 3.12 [d, $J = 7.0$ Hz, 2 β -H(*Phe*)], 3.75 (s, OCH₃), 3.97 (m, 3-H, 4-H), 4.43 [m, α -H(*Phe*), α -H(*Ala*)], 4.85 (dd, $J = 7.0, 14.0$ Hz, 4'-H), 6.63 (d, $J = 8.0$ Hz, 2N-H), 7.18 (s, 5arom H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-alanylglycine benzyl ester (**24a**, C₁₆H₂₁N₃O₆S)

From **23a** (1.9 g, 3.8 mmol) by desilylation. Yield 700 mg (48%); colorless crystals; mp 114°C (CHCl₃); $[\alpha]_{\text{D}}^{20} = -7.3^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.2$, CHCl₃); IR: $\bar{\nu} = 3373$ (NH), 1744, 1650 (CO), 1534 (amide), 1308, 1156 (SO₂) cm⁻¹; ¹H NMR (CDCl₃/D₂O): $\delta = 1.33$ (d, $J = 7.0$ Hz, CH₃), 2.69 (d, $J = 6.0$ Hz, 5-H, 5'-H), 3.97 [s, 2 α -H(*Gly*)], 4.00–4.23 [m, α -H(*Ala*), 3-H, 4-H], 4.41 (dd, $J = 7.0, 14.0$ Hz, 4'-H), 5.10 (s, OCH₂), 7.26 (s, 5arom H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-phenylalanylglycine methyl ester (**24b**, C₁₆H₂₁N₃O₆S)

From **23b** (1.7 g, 3.4 mmol) by desilylation. Yield 1.1 g (85%); colorless crystals; mp 136°C (*EtOH*); $[\alpha]_{\text{D}}^{20} = -18.0^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1$, AcOEt); IR: $\bar{\nu} = 3304$ (NH), 1746, 1638 (CO), 1551 (amide), 1314, 1156 (SO₂) cm⁻¹; ¹H NMR (250 MHz, CDCl₃/DMSO-*d*₆): $\delta = 2.52$ (dd, $J = 6.0, 15.0$ Hz, 5-H), 2.67 (dd, $J = 7.5, 15.0$ Hz, 5'-H), 2.89 [d, $J = 7.5$ Hz, β -H(*Phe*)], 3.19 [d, $J = 5$ Hz, β' -H(*Phe*)], 3.70 (s, OCH₃), 3.80 (m, 3-H, 4-H), 3.96 [dd, $J = 6.0, 18.0$ Hz, CH₂(*Gly*)], 4.16 [m, α -H(*Phe*)], 4.77 (dd, $J = 9.0, 13.5$ Hz, 4'-H), 7.07 (m, N-H), 7.22 (s, 5arom H), 7.87 (d, $J = 9.0$ Hz, N-H), 8.04 (d, $J = 9.0$ Hz, N-H) ppm.

N-[(*RS*)-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-alanyl-*L*-phenylalanine methyl ester (**24c**, C₁₇H₂₃N₃O₆S)

From **23c** (1.74 g, 3.4 mmol) by desilylation. Yield 1.1 g (85%); colorless crystals; mp 165°C (CHCl₃); $[\alpha]_{\text{D}}^{20} = +10.4^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃/DMSO); IR: $\bar{\nu} = 3373, 3289$ (NH), 1719, 1648 (CO), 1545 (amide), 1297, 1159 (SO₂) cm⁻¹; ¹H NMR (CDCl₃/DMSO-*d*₆): $\delta = 1.32$ (d, $J = 7.5$ Hz, CH₃), 2.65 (d, $J = 6.0$ Hz, 5-H, 5'-H), 3.19, 3.00 [2dd, $J = 6.0, 13.0$ Hz, 2 β -H(*Phe*)], 3.69 (s, OCH₃), 3.94 (dd, $J = 4.5, 15.0$ Hz, 4-H), 4.00 (m, 3-H), 4.32 [m, α -H(*Phe*), α -H(*Ala*)], 4.74 (dd, $J = 7.0, 15.0$ Hz, 4'-H), 7.05 (m, 2N-H), 7.21 (s, 5arom H), 7.60, 7.65 (d, $J = 7.0$ Hz, N-H) ppm.

N-[2-[(*RS*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl]-*L*-alanyl-*L*-proline benzyl ester (**25**, C₂₅H₃₉N₃O₆SSi)

From **3** and *L*-Ala-*L*-Pro-OBn-HCl (4.2 g, 13.4 mmol) as described for **15**. Yield 4.9 g (91%); colorless liquid; $[\alpha]_{\text{D}}^{20} = -47.77^{\circ} \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3300$ (NH), 1745, 1630 (CO), 1315, 1150

(SO₂) cm⁻¹; ¹H NMR: δ = 0.23 [s, Si(CH₃)₂], 0.93 [s, C(CH₃)₃], 1.27 (d, J = 9.0 Hz, CH₃), 2.00 [m, 2 β -H(*Pro*), 2 γ -H(*Pro*)], 2.73 (m, 5-H, 5'-H), 3.63 [m, 2 δ -H(*Pro*)], 3.96 (dd, J = 4.0, 13.0 Hz, 4-H), 3.96 (m, 3-H), 4.63 (dd, J = 9.0, 13.0 Hz, 4'-H), 4.63 [m, α -H(*Ala*), α -H(*Pro*)], 5.15 (s, OCH₂), 7.03 (d, J = 9.0 Hz, N-H), 7.30 (s, 5arom H) ppm; MS: m/z (%) = 538 (27.58, M⁺+1), 57 (23.67, C(CH₃)₃⁺), 91 (100, benzyl).

N-[*(RS)*-(1,1-Dioxo-1,2-thiazetidine-3-yl)acetyl]-*L*-alanyl-*L*-proline benzyl ester
(**26**, C₁₉H₂₅N₃O₆S)

From **25** (2.3 g, 4.3 mmol) by desilylation. Yield 500 mg (28%); colorless crystals; mp 130°C (*EtOH*); $[\alpha]_D^{20} = -70.6^\circ \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.7$, CHCl₃); IR: $\bar{\nu} = 3285$ (NH), 1739, 1631 (CO), 1550 (NH), 1300, 1159 (SO₂) cm⁻¹; ¹H NMR (100 MHz): δ = 1.26 (d, J = 7.5 Hz, CH₃), 1.97 [m, β -H(*Pro*), 2 γ -H(*Pro*)], 2.20 [m, β -H(*Pro*)], 2.55, 2.61 (dd, J = 5.5, 15.0 Hz, 5-H), 2.65 (dd, J = 7.5, 17.5 Hz, 5'-H), 3.58, 3.70 [m, 2 δ -H(*Pro*)], 3.88 (m, 3-H), 3.92 (dd, J = 4.5, 13.0 Hz, 4-H), 4.26 (dd, J = 9.0, 14.0 Hz, 4'-H), 4.49 [t, J = 4.5 Hz, α -H(*Pro*)], 4.72 [m, α -H(*Ala*)], 5.11 (dd, J = 12.0 Hz, OCH₂), 6.32, 6.48 (2s, N-H), 7.30 (s, 5arom H) ppm; ¹³C-NMR: δ = 17.45 (CH₃), 24.80 [C- γ (*Pro*)], 28.81 [C- β (*Pro*)], 37.70, 37.89 (C-3), 40.68, 41.06 (C-5), 46.37, 46.62 [C- α (*Ala*)], 46.92 [C- δ (*Pro*)], 59.07 [C- α (*Pro*)], 64.55 (C-4), 66.90 (OCH₂), 128.07, 128.35, 128.52, 135.36 (arom C), 168.74 [CO(ester)], 171.32 [CO(*Ala*)], 171.52 [CO(*Pro*)] ppm.

N-[2-[*(RS)*-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl]-*L*-alanyl-*L*-proline (**27**, C₁₈H₃₃N₃O₆SSi)

From **25** (0.4 g, 0.74 mmol) by hydrogenolysis as **19**. Yield 0.31 g (90%); colorless liquid; $[\alpha]_D^{20} = -65.8^\circ \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.2$, CHCl₃); IR (film): $\bar{\nu} = 3350$ (NH), 1750, 1640 (CO), 1315, 1160 (SO₂) cm⁻¹; ¹H NMR (250 MHz): δ = 0.24 [s, Si(CH₃)₂], 0.97 [s, C(CH₃)₃], 1.28 (d, J = 6.0 Hz, CH₃), 2.04–2.43 [m, 2 β -H(*Pro*), 2 γ -H(*Pro*)], 2.63, 2.68 (dd, J = 10.0, 17.0 Hz, 5-H), 2.70, 2.81 (dd, J = 4.0, 17.0 Hz, 5'-H), 3.58–3.73 [m, 2 δ -H(*Pro*)], 3.95 (dd, J = 3.0, 13.0 Hz, 4-H), 3.95 (m, 3-H), 3.96, 4.00 (dd, J = 4.0, 15.0 Hz, 4-H), 4.45 [m, α -H(*Pro*), α -H(*Ala*)], 4.47, 4.75 (dd, J = 8.0, 15.0 Hz, 4'-H), 5.78 (s, COOH), 7.54, 7.60 (2d, J = 7.0 Hz, N-H) ppm; MS: m/z (%) = 448 (1.16, M⁺+1), 57 (41.27, C(CH₃)₃⁺), 390 (2.05, M⁺-isobutyl), 188 (1.88, M⁺-*Ala-Pro*), 115 (14.5, *TBDMS*), 70 (100, pyrrolidene).

N-[2-[*(RS)*-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidine-3-yl]acetyl]-*L*-alanylglycine (**28**, C₁₅H₂₉N₃O₆SSi)

From **23a** (0.4 g, 0.8 mmol) by hydrogenolysis as **19**. Yield 0.29 g (90%); colorless liquid; $[\alpha]_D^{20} = +16.3^\circ \text{ cm}^2 \text{ g}^{-1}$ ($c = 1.1$, CHCl₃); IR (film): $\bar{\nu} = 3330$ (NH), 1735, 1650 (CO), 1545 (amide), 1305, 1150, 1070 (SO₂) cm⁻¹; ¹H NMR: δ = 0.28 [s, Si(CH₃)₂], 0.96 [s, C(CH₃)₃], 1.34 (d, J = 9.0 Hz, CH₃), 2.78 (m, 5-H, 5'-H), 3.94 [s, 2 α -H(*Gly*)], 3.79–4.19 (m, 3-H, 4-H), 4.49 (dd, J = 9.0, 14.0 Hz, 4'-H), 4.49 [m, α -H(*Ala*)], 7.46 (s, COOH), 8.01 (s, 2N-H) ppm; MS: m/z (%) = 408 (1.89, M⁺+1), 57 (15.36, C(CH₃)₃⁺), 263 (1.26, M⁺-*Ala-Gly*), 147 (100, M⁺-*Ala-Gly-TBDMS*), 145 (12.52, *Ala-Gly*), 115 (5.43, *TBDMS*).

4,4-Dimethyl-1,2-thiazetidine 1,1-dioxide (**29**)

See Ref. [17].

Benzyl 4,4-dimethyl-1,2-thiazetidine-2-acetate 1,1-dioxide (**30**, C₁₃H₁₇NO₄S)

At -78°C under N₂ 2.2 cm³ of *BuLi* (3.52 mmol) were added to a solution of **29** (470 mg, 3.48 mmol) in 30 cm³ of *THF*. After 5 min 5 cm³ of *HMPT*, and 0.66 cm³ of benzyl bromoacetate (4.14 mmol) were

added. After stirring for 1 h, 100 cm³ of *DE* were added, the mixture was washed with a satd. solution of NH₄Cl (3 × 100 cm³), the organic layer was dried (Na₂SO₄), evaporated, and the residue was purified by FC (*DE*:cyclohexane = 1:1). Yield 770 mg (78%); colorless solid; mp 59.5–61°C; *R*_f = 0.23; IR (film): $\bar{\nu}$ = 2968, 2932, 2878 (CH), 1746 (CO), 1309, 1129 (SO₂) cm⁻¹; ¹H NMR (300 MHz): δ = 1.60 (s, 2CH₃), 3.13 (s, 3-H, 3'-H), 3.80 (s, CH₂), 5.17 (s, OCH₂), 7.33 (s, 5arom H) ppm; ¹³C NMR: δ = 21.9 (CH₃), 46.5 (C-3), 52.5 (CH₂), 67.1 (OCH₂), 74.5 (C-4), 128.3, 128.5, 134.9 (arom C), 167.7 (CO) ppm; MS (CI/isobutane): *m/z* (%) = 322 (3.2), 284 (100, M⁺+1), 260 (1.8), 256 (13.3), 220 (85.4).

[2-(4,4-Dimethyl-1,1-dioxo-1,2-thiazetidino-2-yl)acetyl]-*D*-alanyl-*D*-alanine benzyl ester (**31**, C₁₉H₂₇N₃O₆S)

Compound **30** (200 mg, 0.71 mmol) was hydrogenated as described for **19**. The residue was dissolved in 3 cm³ of *DMF*, pentafluorophenol (155 mg, 0.84 mmol) was added, the mixture was cooled to -20°C, then *EDC* (135 mg, 0.71 mmol) was added, the mixture was stirred at room temperature for 12 h, 30 cm³ of *AcOEt* were added, the mixture was washed with a satd. solution of NH₄Cl (3 × 30 cm³), the organic layer was dried (Na₂SO₄), evaporated *in vacuo*, and the residue was dissolved in 3 cm³ of CH₂Cl₂, and *D-Ala-D-Ala-OBn*, prepared from *Boc-D-Ala-D-Ala-OBn* (131 mg, 0.24 mmol), and triethylamine (50 mg, 0.50 mmol) were added. After stirring for 12 h, 50 cm³ of *AcOEt* were added, the mixture was washed with 50 cm³ of a satd. solution of NH₄Cl, the organic layer was dried (Na₂SO₄), evaporated *in vacuo*, and the residue was purified by FC (*AcOEt*). Yield 47 mg (16%); yellow viscous liquid; *R*_f = 0.4 (*AcOEt*); [α]_D²⁷ = +30.2° cm² g⁻¹ (*c* = 0.5, *AcOEt*); IR (film): $\bar{\nu}$ = 3423 (NH), 1739, 1661 (CO), 1302, 1168 (SO₂) cm⁻¹; ¹H NMR (300 MHz): δ = 1.38, 1.40 [2d, *J* = 5.0 Hz, 2CH₃(*Ala*)], 1.65, 1.68 [2s, 2CH₃(C-4)], 3.08 (dd, *J* = 6.0 Hz, 3-H, 3'-H), 3.69 [dd, *J* = 17.0 Hz, CH₂(N)], 4.42–4.61 [m, 2CH(*Ala*)], 5.15 (dd, *J* = 12.0 Hz, OCH₂), 6.53 (d, *J* = 7.0 Hz, N-H), 7.09 (d, *J* = 8.0 Hz, N-H), 7.26–7.38 (m, 5arom H) ppm; ¹³C-NMR: δ = 17.4, 17.5 [CH₃(*Ala*)], 21.3, 21.5 [CH₃(C-4)], 47.7 (C-3), 48.1, 48.5 [CH(*Ala*)], 52.5 (CH₂), 66.6 (OCH₂), 74.3 (C-4), 127.5, 127.8, 128.0, 134.6 (arom C), 166.4, 170.6 (CON), 171.7 (COO) ppm.

4,4-Dimethyl-*N*-phenyl-1,2-thiazetidino-2-carboxamide 1,1-dioxide (**32**, C₁₁H₁₄N₂O₃S)

Compound **29** (200 mg, 1.47 mmol), phenyl isocyanate (175 mg, 1.47 mmol), and dibutyltin dilaurate (3 drops) in 40 cm³ of C₆H₆ were refluxed for 3 h. Then, the solvent was evaporated, and the residue was purified by FC (*AcOEt*:cyclohexane = 1:1). Yield 227 mg (61%); colorless solid; mp 165–167°C; *R*_f = 0.45; IR: $\bar{\nu}$ = 3280 (NH), 1664 (CO), 1320, 1176, 1122 (SO₂) cm⁻¹; ¹H NMR (300 MHz, acetone-d₆): δ = 1.69 (s, 2CH₃), 3.64 (s, 3-H, 3'-H), 7.07–7.56 (m, 5arom H), 8.23 (s, N-H) ppm; ¹³C NMR (acetone-d₆): δ = 21.9 (CH₃), 49.6 (C-3), 75.2 (C-4), 120.9, 124.6, 129.5, 139.1 (arom C), 150.1 (CO) ppm.

2-[(*S*)-2-(*tert*-Butyldimethylsilyl)-1,1-dioxo-1,2-thiazetidino-3-yl]acetyl-*D*-alanyl-*D*-alanine benzyl ester (**33**, C₂₃H₃₇N₃O₆SSi)

From **8** (230 mg, 0.62 mmol), pentafluorophenol (140 mg, 0.74 mmol), *EDC* (118 mg, 0.62 mmol), and *D-Ala-D-Ala-OBn*, prepared from *Boc-D-Ala-D-Ala-OBn* (131 mg, 0.24 mmol), as described for **31**. Yield 90 mg (28.4%); yellow viscous liquid; ¹H NMR (300 MHz): δ = 0.26, 0.28 [2s, Si(CH₃)₂], 0.98 [s, C(CH₃)₃], 1.37, 1.43 [2d, *J* = 7.1 Hz, 2CH₃(*Ala*)], 2.67 (dd, *J* = 10.0, 15.0 Hz, 5-H), 2.83 (dd, *J* = 4.0, 15.0 Hz, 5'-H), 3.91–4.26 (m, 3-H, 4-H, 4'-H), 4.33–4.63 [m, 2CH(*Ala*)], 5.18 (dd, *J* = 12.2 Hz, OCH₂), 6.48, 6.50 (2s, 2N-H), 7.30–7.37 (m, 5arom H) ppm.

Boc-Cys(SBn)-D-Ala-OBn (**34**, C₂₅H₃₂N₂O₅S)

Boc-L-Cys(SBn)-OH (2.0 g, 6.4 mmol), *NHS* (1.47 g, 7.0 mmol), *D-Ala-OBn-p-Ts* (2.25 g, 6.4 mmol), and 0.9 cm³ of triethylamine (6.4 mmol) were dissolved in 20 cm³ of *DMF*, cooled to -20°C, and *DCC* (1.45 g,

7.0 mmol) was added. After stirring for 12 h, 100 cm³ of *AcOEt* were added, the mixture was washed with a satd. solution of NH₄Cl (2 × 100 cm³), the organic layer was dried (Na₂SO₄), evaporated *in vacuo*, and the residue was purified by FC (*AcOEt*:cyclohexane = 1:2). Yield 2.15 g (71%); colorless solid; mp 74–76°C; $R_f = 0.55$; $[\alpha]_D^{27} = +21.8^\circ \text{ cm}^2 \text{ g}^{-1}$ ($c = 1$, *AcOEt*); IR: $\bar{\nu} = 3334$ (NH), 1730, 1689, 1652 (CO) cm⁻¹; ¹H NMR (300 MHz): $\delta = 1.41$ [d, $J = 7.0$ Hz, CH₃(*Ala*)], 1.46 [s, C(CH₃)₃], 2.75 [dd, $J = 7.0, 14.0$ Hz, β -H(*Cys*)], 2.86 [dd, $J = 6.0, 14.0$ Hz, β' -H(*Cys*)], 3.73 (dd, $J = 13.0$ Hz, SCH₂), 4.25 [m, α -H(*Cys*)], 4.55–4.65 [m, α -H(*Ala*)], 5.17 (dd, $J = 12.0$ Hz, OCH₂), 5.23 (s, NH₂), 6.73 (d, N–H), 7.27–7.40 (m, 10arom H) ppm.

N-[*(R)*-(1,1-Dioxo-1,2-thiazetidine-3-yl)carbonyl]-*D*-alanine benzyl ester

(**35**, C₁₃H₁₆N₂O₅S)

The mixture of **34** (2.15 g, 4.55 mmol), 15 cm³ of *TFA*, and 4.2 cm³ of propane-2-thiol was stirred at room temperature for 2 h. After evaporation *in vacuo*, 100 cm³ of a solution of Na₂CO₃ (10%) were added, the mixture was extracted with 2 × 100 cm³ of *DE*, and a satd. solution of HCl was added to the combined organic layers. After storing for 24 h at 0°C, the solvent was separated, the residue was dried *in vacuo*, and dissolved in a mixture of 5 cm³ of acetic acid and 0.7 cm³ of H₂O. With cooling to <20°C, the mixture was saturated with Cl₂ for about 15 min, poured into 50 cm³ of pentane, and stirred for 5 min. The organic layer was separated, the residue was dissolved in 50 cm³ of *THF*, and triethylamine was added until the *pH* was alkaline. After stirring for 1 h, 100 cm³ of *AcOEt* were added, the mixture was washed with 100 cm³ of a satd. solution of NH₄Cl, the organic layer was dried (Na₂SO₄), evaporated *in vacuo*, and the residue was purified by FC (*AcOEt*:cyclohexane = 2:1; then *AcOEt*). Yield 340 mg (24%); colorless solid; mp 117–119°C; $R_f = 0.33$ (*AcOEt*:cyclohexane = 2:1); $[\alpha]_D^{25} = -36.0^\circ \text{ cm}^2 \text{ g}^{-1}$ ($c = 0.05$, acetone); IR: $\bar{\nu} = 3324, 3279$ (NH), 1742, 1668 (CO), 1346, 1157 (SO₂) cm⁻¹; ¹H NMR (300 MHz, acetone-d₆): $\delta = 1.44$ (d, $J = 7.0$ Hz, CH₃), 4.14–4.21 (m, 3-H), 4.24 (dd, $J = 6.0, 12.0$ Hz, 4-H), 4.50–4.62 [m, α -H(*Ala*)], 4.62 (dd, $J = 3.0, 12.0$ Hz, 4'-H), 5.18 (dd, $J = 13.0$ Hz, OCH₂), 7.27–7.40 (m, 5arom H), 7.43, 7.66 (2s, 2N–H) ppm; ¹³C NMR (acetone-d₆): $\delta = 17.5$ (CH₃), 40.9 (C-3), 49.1 [CH(*Ala*)], 65.6 (C-4), 67.3 (OCH₂), 128.8, 128.9, 129.3, 137.0 (arom C), 169.5 (CON), 172.7 (COO) ppm.

Acknowledgments

We thank Prof. Dr. G. Blaschke, Münster, for some HPLC experiments, PD Dr. Thomas Jira, Greifswald, for the CD spectra, and Ursula Predoiu, Institute of Pharmacy, Freiburg, for technical help. Furthermore, we wish to thank Degussa AG, for generous support with chemicals, E. Merck KGaG, Darmstadt, for continuous support with chromatography materials, chemicals, and HPLC experiments, and we thank the “Fonds der Chemischen Industrie” for financial support. B.A.T. thanks the DAAD for a study (Ph.D.) grant.

References

- [1] Röhrich T, Abu Thaher B, Otto H-H (2003) *Monatsh Chem* **134**: Online First Oct 20, 2003
- [2] Schneider M, Otto H-H (2001) *Arch Pharm* **334**: 167
- [3] Schwenkkraus P (1987) PhD Thesis, University of Freiburg
- [4] Birkhofer L, Birkhofer A (1956) *Chem Ber* **89**: 1226
- [5] Miller HK, Waelsch H (1952) *J Am Chem Soc* **24**: 1092
- [6] Keglevic D, Ladesic B (1959) *Cro Chem Acta* **31**: 57
- [7] Halstrøm J, Schou O, Kovács K, Brunfeldt K (1970) *Hoppe-Seyler's Z Physiol Chem* **351**: 1576
- [8] Stanfield CF, Parker JE, Kanellis P (1981) *J Org Chem* **46**: 4797
- [9] Hooz J, Gilani SSH (1968) *Can J Chem* **46**: 86

- [10] Wendlberger G (1984) In: Houben-Weyl, Müller E (eds) *Methoden der organischen Chemie*, vol XV/2, 4th ed. Thieme, Stuttgart, p 103
- [11] See Ref. [10], p 111
- [12] See Ref. [10], p 149
- [13] Stelzel P (1984) In: Houben-Weyl, Müller E (eds) *Methoden der organischen Chemie*, vol XV/1, 4th ed. Thieme, Stuttgart, p 187
- [14] Corey EJ, Venkateswarlu A (1972) *J Am Chem Soc* **94**: 6190; Ona H, Uyeo S (1984) *Tetrahedron Lett* **25**: 2237
- [15] Anwer MK, Spatola AF (1983) *J Org Chem* **48**: 3503; Bernotas RC, Cube RV (1990) *Synthetic Commun* **20**: 1209
- [16] Colvin E (1981) *Silicon in Organic Synthesis*. Butterworths, London, p 184
- [17] Müller M, Otto H-H (1991) *Arch Pharm* **324**: 15
- [18] Meyle E, Schwenkkraus P, Zsigmondy M, Otto H-H (1989) *Arch Pharm* **322**: 17
- [19] Merkle S (1992) PhD Thesis, University of Freiburg